[1] |
WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu.
Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
|
[2] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
[3] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
[4] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
[5] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
[6] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[7] |
YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen.
Research progress in plasma concentration monitoring of rivaroxaban
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
|
[8] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[9] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[10] |
CHEN Manxin, ZHANG Bingyu, DAI Min.
Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
|
[11] |
LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao.
Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
|
[12] |
LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua.
Research progress in population pharmacokinetics of rituximab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
|
[13] |
ZHANG Qiang, ZHENG Huajun, LI Quan.
Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
|
[14] |
YU Yahong, SONG Yu.
Pharmacotherapy of patients with left ventricular assist devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 198-204.
|
[15] |
WANG Dan, YAN Xiaoli, ZHANG Yuan.
Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
|